Tumor-Activated Benzothiazole Inhibitors of Stearoyl-CoA Desaturase
datasetposted on 19.08.2020 by Noelle S. Williams, Stephen Gonzales, Jacinth Naidoo, Giomar Rivera-Cancel, Sukesh Voruganti, Prema Mallipeddi, Panayotis C. Theodoropoulos, Sophie Geboers, Hong Chen, Francisco Ortiz, Bruce Posner, Deepak Nijhawan, Joseph M. Ready
Datasets usually provide raw data for analysis. This raw data often comes in spreadsheet form, but can be any collection of data, on which analysis can be performed.
A series of N-acyl benzothiazoles shows selective and potent cytotoxicity against cancer cell lines expressing cytochrome P450 4F11. A prodrug form is metabolized by cancer cells into an active inhibitor of stearoyl-CoA desaturase (SCD). Substantial variation on the acyl portion of the inhibitors allowed the identification of (R)-27, which balanced potency, solubility, and lipophilicity to allow proof-of-concept studies in mice. The prodrugs were activated inside the tumor, where they can arrest tumor growth. Together, these observations offer promise that a tumor-activated prodrug strategy might exploit the essentiality of SCD for tumor growth, while avoiding toxicity associated with systemic SCD inhibition.